leisure time -WSS

leisure time

author：knowledge 2025-09-03 09:26:51 - browse：82359

JOSEPH PREZIOSO/AFP via Getty Images

LONDON — The U.K.’s cost-effectiveness watchdog said Thursday it is not yet recommending Vertex’s CRISPR-based therapy for sickle cell disease, saying in draft guidance it has questions about the medicine’s lasting benefits for patients.

U.K. regulators approved the therapy, known as Casgevy or exa-cel, last year, granting it the world’s first authorization for any CRISPR-based medicine. But observers have been watching to see how the U.K.’s National Institute for Health and Care Excellence, as well as similar agencies in European countries, would view the pricey, one-time therapy. NICE needs to recommend the therapy for it to be offered in the National Health Service.

In the U.S., Casgevy has a list price of $2.2 million. It was developed by Vertex in partnership with CRISPR Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： ASCO Takeaways: Winners, snoozers, and the art of cancer care

WSS

How Brent Saunders' Allergan experiment failed

Eli Lilly’s Zepbound improved liver scarring in mid

Data don't support strong claims for Covid

Take antibiotics after sex, CDC recommends for certain risk groups

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

Finland to offer bird flu vaccine to select groups of people, a possible global first

knowledge

leisure time

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Stopping antidepressants leads to symptoms for 1 in 6 patients

The cancer drug shortage isn’t new — and neither are the solutions

Biden, Billy Joel, Elton John lead tributes for Tony Bennett after singer's death at 96

Alkermes shareholders re

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Medicare proposal to cover medical devices draws a mixed reaction

'The View' co

As demand for Covid shots wanes, Moderna seeks its next success

Anthony Fauci pushes back on GOP claims during Covid hearing

knowledge

EMA weighs against approval for Mirati's lung cancer drug

An outdated Medicare rule harms dementia patients with anxiety

Take antibiotics after sex, CDC recommends for certain risk groups

Why Marc Tessier

New chief aims to remake Sanofi Genzyme

Take antibiotics after sex, CDC recommends for certain risk groups

focus

focus

focus

hotspot